Editorial: The Evolving Landscape of Stereotactic Body Radiation Therapy for the Management of Prostate Cancer

Overview

Journal Front Oncol

Specialty Oncology

Date 2021 Jan 1

PMID 33384965

Authors

Seth R Blacksburg

Donald B Fuller

Jonathan A Haas

Affiliations

Soon will be listed here.

References

Baker B, Basak R, Mohiuddin J, Chen R . Use of stereotactic body radiotherapy for prostate cancer in the United States from 2004 through 2012. Cancer. 2016; 122(14):2234-41. DOI: 10.1002/cncr.30034. View

van de Water S, Valli L, Aluwini S, Lanconelli N, Heijmen B, Hoogeman M . Intrafraction prostate translations and rotations during hypofractionated robotic radiation surgery: dosimetric impact of correction strategies and margins. Int J Radiat Oncol Biol Phys. 2014; 88(5):1154-60. DOI: 10.1016/j.ijrobp.2013.12.045. View

Culp S, Schellhammer P, Williams M . Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study. Eur Urol. 2013; 65(6):1058-66. DOI: 10.1016/j.eururo.2013.11.012. View

Hegde J, Collins S, Fuller D, King C, Demanes D, Wang P . A Pooled Analysis of Biochemical Failure in Intermediate-risk Prostate Cancer Following Definitive Stereotactic Body Radiotherapy (SBRT) or High-Dose-Rate Brachytherapy (HDR-B) Monotherapy. Am J Clin Oncol. 2016; 41(5):502-507. DOI: 10.1097/COC.0000000000000311. View

Kotecha R, Djemil T, Tendulkar R, Reddy C, Thousand R, Vassil A . Dose-Escalated Stereotactic Body Radiation Therapy for Patients With Intermediate- and High-Risk Prostate Cancer: Initial Dosimetry Analysis and Patient Outcomes. Int J Radiat Oncol Biol Phys. 2016; 95(3):960-964. DOI: 10.1016/j.ijrobp.2016.02.009. View

Meier R . Dose-Escalated Robotic SBRT for Stage I-II Prostate Cancer. Front Oncol. 2015; 5:48. PMC: 4387928. DOI: 10.3389/fonc.2015.00048. View

Burdett S, Boeve L, Ingleby F, Fisher D, Rydzewska L, Vale C . Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis. Eur Urol. 2019; 76(1):115-124. PMC: 6575150. DOI: 10.1016/j.eururo.2019.02.003. View

Rusthoven C, Jones B, Flaig T, Crawford E, Koshy M, Sher D . Improved Survival With Prostate Radiation in Addition to Androgen Deprivation Therapy for Men With Newly Diagnosed Metastatic Prostate Cancer. J Clin Oncol. 2016; 34(24):2835-42. DOI: 10.1200/JCO.2016.67.4788. View

Palma D, Olson R, Harrow S, Gaede S, Louie A, Haasbeek C . Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet. 2019; 393(10185):2051-2058. DOI: 10.1016/S0140-6736(18)32487-5. View

10.

Buyyounouski M, Price Jr R, Harris E, Miller R, Tome W, Schefter T . Stereotactic body radiotherapy for primary management of early-stage, low- to intermediate-risk prostate cancer: report of the American Society for Therapeutic Radiology and Oncology Emerging Technology Committee. Int J Radiat Oncol Biol Phys. 2010; 76(5):1297-304. DOI: 10.1016/j.ijrobp.2009.09.078. View

11.

Morgan S, Hoffman K, Loblaw D, Buyyounouski M, Patton C, Barocas D . Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline. J Clin Oncol. 2018; :JCO1801097. PMC: 6269129. DOI: 10.1200/JCO.18.01097. View

12.

Levin-Epstein R, Jiang N, Wang X, Upadhyaya S, Collins S, Suy S . Dose-response with stereotactic body radiotherapy for prostate cancer: A multi-institutional analysis of prostate-specific antigen kinetics and biochemical control. Radiother Oncol. 2020; 154:207-213. PMC: 7956167. DOI: 10.1016/j.radonc.2020.09.053. View

13.

Stone N, Ratnow E, Stock R . Prior transurethral resection does not increase morbidity following real-time ultrasound-guided prostate seed implantation. Tech Urol. 2000; 6(2):123-7. View

14.

Widmark A, Gunnlaugsson A, Beckman L, Thellenberg-Karlsson C, Hoyer M, Lagerlund M . Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Lancet. 2019; 394(10196):385-395. DOI: 10.1016/S0140-6736(19)31131-6. View

15.

Chen L, Suy S, Uhm S, Oermann E, Ju A, Chen V . Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience. Radiat Oncol. 2013; 8:58. PMC: 3610192. DOI: 10.1186/1748-717X-8-58. View

16.

Koontz B, Bossi A, Cozzarini C, Wiegel T, DAmico A . A systematic review of hypofractionation for primary management of prostate cancer. Eur Urol. 2014; 68(4):683-91. DOI: 10.1016/j.eururo.2014.08.009. View

17.

Gonzalez-Motta A, Roach 3rd M . Stereotactic body radiation therapy (SBRT) for high-risk prostate cancer: Where are we now?. Pract Radiat Oncol. 2018; 8(3):185-202. DOI: 10.1016/j.prro.2017.11.008. View

18.

Weckermann D, Polzer B, Ragg T, Blana A, Schlimok G, Arnholdt H . Perioperative activation of disseminated tumor cells in bone marrow of patients with prostate cancer. J Clin Oncol. 2009; 27(10):1549-56. DOI: 10.1200/JCO.2008.17.0563. View

19.

Wang K, Chen R, Kane B, Medbery C, Underhill K, Gray J . Patient and Dosimetric Predictors of Genitourinary and Bowel Quality of Life After Prostate SBRT: Secondary Analysis of a Multi-institutional Trial. Int J Radiat Oncol Biol Phys. 2018; 102(5):1430-1437. DOI: 10.1016/j.ijrobp.2018.07.191. View

20.

Fuller D, Falchook A, Crabtree T, Kane B, Medbery C, Underhill K . Phase 2 Multicenter Trial of Heterogeneous-dosing Stereotactic Body Radiotherapy for Low- and Intermediate-risk Prostate Cancer: 5-year Outcomes. Eur Urol Oncol. 2019; 1(6):540-547. DOI: 10.1016/j.euo.2018.06.013. View